
|Articles|November 15, 2003
NEI to test intraocular implant to thwart RP
Paris-Neurotech SA is initiating a phase I clinical trial of NT-501, its lead Encapsulated Cell Technology (ECT) product for the treatment of retinitis pigmentosa (RP).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
2
From then to next: Five decades of transformation in ophthalmology
3
Kodiak Sciences releases follow-up, 20-week data from APEX study
4
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
5


















































.png)


